130 related articles for article (PubMed ID: 21682353)
1. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis.
Mueller D; Gandjour A
Appl Health Econ Health Policy; 2011 Jul; 9(4):259-73. PubMed ID: 21682353
[TBL] [Abstract][Full Text] [Related]
2. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
Mueller D; Gandjour A
Appl Health Econ Health Policy; 2008; 6(2-3):113-35. PubMed ID: 19231905
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
Mueller D; Gandjour A
Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention of osteoporosis: mass screening scenario or prescreening with questionnaires? An economic perspective.
Richy F; Ethgen O; Bruyere O; Mawet A; Reginster JY
J Bone Miner Res; 2004 Dec; 19(12):1955-60. PubMed ID: 15537437
[TBL] [Abstract][Full Text] [Related]
7. Potential clinical and economic impact of nonadherence with osteoporosis medications.
Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility and budget impact analysis of primary prevention with alendronate of osteoporotic hip fractures in Catalonia.
Pueyo MJ; Larrosa M; Surís X; Garcia-Ruiz AJ
Reumatol Clin; 2012; 8(3):128-34. PubMed ID: 22421456
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women.
Christensen PM; Brixen K; Gyrd-Hansen D; Kristiansen IS
Basic Clin Pharmacol Toxicol; 2005 May; 96(5):387-96. PubMed ID: 15853932
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Hiligsmann M; Bruyère O; Reginster JY
Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women.
Nagata-Kobayashi S; Shimbo T; Fukui T
J Bone Miner Metab; 2002; 20(6):350-7. PubMed ID: 12434163
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
[TBL] [Abstract][Full Text] [Related]
13. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
14. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
Tscheulin DK; Drevs F
Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
[TBL] [Abstract][Full Text] [Related]
15. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
[TBL] [Abstract][Full Text] [Related]
16. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
17. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?
Sanders KM; Nicholson GC; Watts JJ; Pasco JA; Henry MJ; Kotowicz MA; Seeman E
Bone; 2006 May; 38(5):694-700. PubMed ID: 16507356
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Goeree R; Blackhouse G; Adachi J
Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis.
Mueller D; Weyler E; Gandjour A
Pharmacoeconomics; 2008; 26(6):513-36. PubMed ID: 18489201
[TBL] [Abstract][Full Text] [Related]
20. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients.
Hiligsmann M; Rabenda V; Bruyère O; Reginster JY
Health Policy; 2010 Jul; 96(2):170-7. PubMed ID: 20153543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
